# reload+after+2024-01-21 15:46:19.285922
address1§1 Bridge Plaza
address2§Suite 275
city§Fort Lee
state§NJ
zip§07024
country§United States
phone§201 614 3150
website§https://www.nuvectis.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
fullTimeEmployees§11
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Ron  Bentsur M.B.A.', 'age': 57, 'title': 'Co-Founder, Chairman, CEO & President', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 851610, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Enrique  Poradosu Ph.D.', 'age': 56, 'title': 'Co-Founder, Executive VP, Chief Scientific & Business Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 549072, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Shay  Shemesh', 'age': 39, 'title': 'Co-Founder, Executive VP, Chief Development & Operations Officer', 'yearBorn': 1984, 'fiscalYear': 2022, 'totalPay': 529268, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael  Carson CPA', 'age': 47, 'title': 'Vice President of Finance', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§10
compensationRisk§8
shareHolderRightsRisk§6
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
currency§USD
dateShortInterest§1702598400
forwardEps§-1.46
exchange§NCM
quoteType§EQUITY
shortName§Nuvectis Pharma, Inc.
longName§Nuvectis Pharma, Inc.
firstTradeDateEpochUtc§1643985000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§e0782c4f-f6b0-3978-be3c-82232bb8af27
gmtOffSetMilliseconds§-18000000
targetHighPrice§21.0
targetLowPrice§20.0
targetMeanPrice§20.67
targetMedianPrice§21.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§3.956
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
